Jump to the top of the page

Investment Banking

The Quarterly Rx: Q2 2023 U.S. Biopharma Recap

Biopharma markets closed the first half of 2023 with renewed optimism and an encouraging outlook for the rest of the year. That comes as major market indices have trended upward—with biopharma emerging as the most heavily weighted sector in the Russell 2000—despite macro concerns following the regional banking crisis.

Public financing markets have warmed, but private companies continue to face challenging decisions amid a slow IPO market and selective private financing market. Simultaneously, SMID-cap M&A helped recycle capital in the sector.

William Blair’s Biopharma team shares perspectives in the Quarterly Rx: Q2 2023 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Cboe Global Markets, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Cboe Global Markets, Inc. (CBOE $190.84), a leading derivatives and securities exchange network that provides trading, clearing, data, and technology solutions to a broad range of market participants globally.

    Read more
  • Record 21 William Blair Wealth Management Teams Named Forbes Best-in-State

    Congratulations to the record 21 William Blair wealth management teams recognized in the Forbes Best-in-State list, released January 9.

    Read more
  • An AI Inflection Point for Insurtech

    The technology necessary to deliver cutting-edge AI solutions across the insurance ecosystem appears to have finally arrived—with the potential to spur a new wave of investment and transaction activity.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures